Selection of Patients with Hepatocellular Carcinoma for Sorafenib

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.7, Iss.4, 2009-04, pp. : 397-403

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sorafenib: activity and clinical application in patients with hepatocellular carcinoma

By Guan Yong-Song He Qing

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 2, 2011-02 ,pp. : 303-313

Informa Healthcare

Access to resources Recommend Favorite

Sorafenib: In Hepatocellular Carcinoma

By Simpson Dene Keating Gillian M.

Drugs, Vol. 68, Iss. 2, 2008-01 ,pp. : 251-258

Adis International

Access to resources Recommend Favorite

Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development

Current Medicinal Chemistry, Vol. 19, Iss. 7, 2012-03 ,pp. : 938-944

Bentham Science Publishers

Access to resources Recommend Favorite

Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma

By Lee Su

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1540-1547

Springer Publishing Company

Access to resources Recommend Favorite

Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 69, Iss. 10, 2014-10 ,pp. : 759-763

Govi-Verlag

Access to resources Recommend Favorite